Methods and compositions for monitoring and risk prediction...

Details Methods and compositions for monitoring and risk prediction... Methods and compositions for monitoring and risk prediction...

2011-07-26

2011-07-26

Cook, Lisa (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S002000, C435S007100, C436S501000, C436S518000, C436S522000, C422S050000

Reexamination Certificate

active

07985560

ABSTRACT:
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.

REFERENCES:
patent: 4900662 (1990-02-01), Shah et al.
patent: 5202234 (1993-04-01), Shah et al.
patent: 5382515 (1995-01-01), Shah et al.
patent: 5382522 (1995-01-01), Shah et al.
patent: 5480792 (1996-01-01), Buechler et al.
patent: 5525524 (1996-06-01), Buechler et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5631171 (1997-05-01), Sandstrom et al.
patent: 5679526 (1997-10-01), Buechler et al.
patent: 5763189 (1998-06-01), Buechler et al.
patent: 5795725 (1998-08-01), Buechler et al.
patent: 5824799 (1998-10-01), Buechler et al.
patent: 5843690 (1998-12-01), Gargan
patent: 5851776 (1998-12-01), Valkirs
patent: 5885527 (1999-03-01), Buechler
patent: 5922615 (1999-07-01), Nowakowski et al.
patent: 5939272 (1999-08-01), Buechler et al.
patent: 5947124 (1999-09-01), Buechler et al.
patent: 5955377 (1999-09-01), Maul et al.
patent: 5985579 (1999-11-01), Buechler et al.
patent: 6019944 (2000-02-01), Buechler
patent: 6057098 (2000-05-01), Buechler et al.
patent: 6113855 (2000-09-01), Buechler et al.
patent: 6143576 (2000-11-01), Buechler
patent: 6156521 (2000-12-01), Buechler et al.
patent: 6174686 (2001-01-01), Buechler et al.
patent: 6238931 (2001-05-01), Buechler et al.
patent: 6251687 (2001-06-01), Buechler et al.
patent: 6316409 (2001-11-01), Neri et al.
patent: 6579687 (2003-06-01), Buechler et al.
patent: 6627404 (2003-09-01), Buechler et al.
patent: 6939678 (2005-09-01), Buechler et al.
patent: 6991907 (2006-01-01), Buechler et al.
patent: 7341838 (2008-03-01), Buechler et al.
patent: 7358055 (2008-04-01), Valkirs et al.
patent: 7361473 (2008-04-01), Valkirs et al.
patent: 7427490 (2008-09-01), Valkirs
patent: 7842472 (2010-11-01), Valkirs et al.
patent: 2003/0022235 (2003-01-01), Dahlen et al.
patent: 2003/0119064 (2003-06-01), Valkirs et al.
patent: 2003/0199000 (2003-10-01), Valkirs et al.
patent: 2003/0211544 (2003-11-01), Buechler et al.
patent: 2003/0219734 (2003-11-01), Buechler
patent: 2004/0121343 (2004-06-01), Buechler et al.
patent: 2004/0121350 (2004-06-01), Anderberg et al.
patent: 2004/0126767 (2004-07-01), Anderberg et al.
patent: 2004/0171064 (2004-09-01), Dahlen et al.
patent: 2004/0176914 (2004-09-01), Buechler et al.
patent: 2004/0203083 (2004-10-01), Buechler et al.
patent: 2004/0209307 (2004-10-01), Valkirs et al.
patent: 2004/0219509 (2004-11-01), Valkirs et al.
patent: 2004/0219603 (2004-11-01), Devarajan et al.
patent: 2004/0253637 (2004-12-01), Buechler et al.
patent: 2005/0148024 (2005-07-01), Buechler
patent: 2005/0164317 (2005-07-01), Buechler et al.
patent: 2005/0255484 (2005-11-01), Valkirs et al.
patent: 2006/0051825 (2006-03-01), Buechler et al.
patent: 2006/0105419 (2006-05-01), Blankenberg et al.
patent: 2007/0092911 (2007-04-01), Buechler et al.
patent: 2007/0196880 (2007-08-01), Buechler et al.
patent: 2007/0218498 (2007-09-01), Buechler et al.
patent: 2007/0224643 (2007-09-01), McPherson et al.
patent: 2007/0269836 (2007-11-01), McPherson
patent: 2008/0045444 (2008-02-01), Whittaker
patent: 2008/0050832 (2008-02-01), Buechler et al.
patent: 2008/0118924 (2008-05-01), Buechler
patent: 2008/0254485 (2008-10-01), Valkirs et al.
patent: 2008/0293920 (2008-11-01), Buechler
patent: 2009/0061467 (2009-03-01), Buechler et al.
patent: 2010/0086944 (2010-04-01), Valkirs et al.
patent: WO 93/24231 (1993-12-01), None
patent: WO 95/08772 (1995-03-01), None
patent: WO 98/08606 (1998-03-01), None
patent: WO 98/21563 (1998-05-01), None
patent: WO 98/08606 (1998-07-01), None
patent: WO 98/43739 (1998-10-01), None
patent: WO 98/43739 (2001-06-01), None
patent: WO 2004/058055 (2004-07-01), None
patent: WO 2004/058055 (2004-07-01), None
patent: WO 2004/059293 (2004-07-01), None
patent: WO 2004/088276 (2004-10-01), None
patent: WO 2004/088276 (2004-11-01), None
patent: WO 2004/059293 (2005-03-01), None
patent: WO 2005/121788 (2005-12-01), None
patent: WO 2005/121788 (2006-05-01), None
patent: WO 2006/066587 (2006-06-01), None
patent: WO 2008/061149 (2008-05-01), None
patent: WO 2008/061149 (2008-10-01), None
U.S. Appl. No. 60/436,392, filed Dec. 24, 2002, Anderberg et al.
Anderson, L. Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease. J. Physiol. 563.1; 2004: 23-60.
Bachorzewska, et al. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol. Dial. Transplant. 2007;(22):295-296.
Boerrigter, et al. Des-Serine-Proline B-Type Natriuretic Peptide (BNP 3-32) in Cardiorenal Regulation. Am J Physiol Regul Integr Comp Physiol (Oct. 26, 2006).
Buechler, K. Chapter 41, entitled “Near Patient Tests: Triage Cardiac System,” in The Immunoassay Handbook, 2nd ed., David Wild, ed., Nature Publishing Group, 2001.
Cataliotti, et al. Circulating Natriuretic Peptide Concentrations in Patients with End-Stage Renal Disease: Role for Brain Natriuretic Peptide as a Biomarker for Ventricular Remodeling. Mayo Clin. Proc. 2001;76:1111-1119.
Chen et al. The Natriuretic Peptides in Heart Failure: Diagnostic and Therapeutic Potentials. Proceedings of the Assoc of American Physicians. Sep./Oct. 1999; 111(5):406-416.
Cwirla, et al. Peptides on Phage: A Vast Library of Peptides for Identifying Ligands Proc. Natl. Acad. Sci. USA 87:6378-6382 (1990).
Dangas et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J. Cariol. Jan. 1, 2005;95(1):13-9.
Davis et al. Genomic based biomarkers of drug-induced nephrotoxicity. Expert Opin Drug Metab Toxicol. Feb. 2006;2(1):95-101.
Devlin, et al. Random Peptide Libraries: A Source of Specific Protein Binding Molecules Science 249:404-406 (1990).
Fischer et al. Uncomplicated acute renal failure and hospital resource utilization: a retrospective multicenter analysis. Am J Kidney Dis. Dec. 2005;46(6):1049-57.
Fischer, et al. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. Intensive Care Med. Jul. 2003;29(7):1043-51.
Francis, G. Acute decompensated heart failure; the cardiorenal syndrome. Cleve Clin J Med. Jun. 2006;73 Suppl 2:S8-13; discussion S30-3.
Fujiwara, et al. Synthesis of Human C-Type Natriuretic Peptide 22 Using Chlorotrityl Resin and Tetrafluoroboric Acid Deprotection Chem. Pharm. Bull. (Tokyo) 44:1326-1331 (1996).
Goetze et al. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin. Chem. 2002; 48:1035-42.
Gottschling, et al. Cellular solid-phase binding assay and mass spectrometry for screening of alpha 4 beta 7 integrin antagonists. Bioorg Med Chem Lett. Dec. 3, 2001;11(23):2997-3000.
Gruberg et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency.J Am Coll Cardiol. Nov. 1, 2000;36(5):1542-8.
Hanley, et al. The Meaning and Use of the Area under a Receiver Operating Characteristic (ROC) Curve. Radiology 1982;143: 29-36.
Huse, et al. Application of a Filamentous Phage pVIII Fusion Protein System Suitable for Efficient Production, Screening, and Mutagenesis of F(ab) Antibody Fragments J. Immunol. 149:3914-3920 (1992).
International Search Report dated Feb. 13, 2008 from PCT Application No. US 2006/038755.
Kiso, et al, Solution-Phase Synthesis of Porcine Brain Natriuretic Peptide (pBNP) Using S-Trimethylactamido-Methycystein Chem. Pharm. Bull. (Tokyo) 38

Affiliated with

Also associated with

Rating

Methods and compositions for monitoring and risk prediction... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for monitoring and risk prediction..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for monitoring and risk prediction... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2640669